Swan Global Investments LLC Acquires New Position in Cibus, Inc. (NASDAQ:CBUS)

Swan Global Investments LLC purchased a new position in Cibus, Inc. (NASDAQ:CBUS) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 35,123 shares of the company’s stock, valued at approximately $115,000.

Other large investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in Cibus during the 3rd quarter valued at $33,000. Charles Schwab Investment Management Inc. raised its holdings in Cibus by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock valued at $161,000 after buying an additional 6,276 shares during the period. FineMark National Bank & Trust raised its holdings in Cibus by 24.3% during the 2nd quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock valued at $202,000 after buying an additional 4,000 shares during the period. Squarepoint Ops LLC bought a new position in Cibus in the 2nd quarter valued at $214,000. Finally, Rhumbline Advisers bought a new position in Cibus in the 2nd quarter valued at $221,000. 33.81% of the stock is owned by hedge funds and other institutional investors.

Cibus Price Performance

CBUS stock traded up $0.10 during trading on Wednesday, reaching $4.59. 4,975 shares of the company traded hands, compared to its average volume of 135,677. Cibus, Inc. has a 12 month low of $2.86 and a 12 month high of $23.18. The business has a 50 day simple moving average of $3.93 and a 200 day simple moving average of $7.70.

Wall Street Analyst Weigh In

Several equities analysts have commented on CBUS shares. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Cibus in a research report on Monday, November 11th. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price target on shares of Cibus in a research report on Tuesday, October 22nd. Finally, Alliance Global Partners dropped their price target on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research report on Tuesday, September 24th.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.